Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe OCD
NCT04882839 · Beersheva Mental Health Center
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Yale-Brown Obsessive-Compulsive Scale (Y-BOCS ) change from baseline
Measured over Baseline to 6-month follow-up
Obsessive-Compulsive Inventory-Revised (OCI-R) change from baseline
Measured over Baseline to 6-month follow-up
Obsessional Beliefs Questionnaire (OBQ-20) change from baseline
Measured over Baseline to 6-month follow-up
Beck Depression Inventory -II (BDI-II) change from baseline
Measured over Baseline to 6-month follow-up
Beck Anxiety Inventory (BAI) change from baseline
Measured over Baseline to 6-month follow-up
Mini International Neuropsychiatric Interview (M.I.N.I.) change from baseline
Measured over Baseline to end of treatment
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| Beer Sheva Mental Health Center | Beersheba | — | Israel |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT04882839 on ClinicalTrials.gov →
Last updated in the registry 2025-11-19. Registry records change; this page reflects the data build of 2026-08-25.
Related